Boehringer and Cue Biopharma Unite to Target Autoimmune Disease with Precision T-Cell Therapy

In a bold move to reshape how autoimmune diseases are treated, Boehringer Ingelheim and Cue Biopharma have entered a strategic research and licensing collaboration centered on CUE-501—a highly selective B cell depletion therapy in development. Unlike traditional therapies, Cue’s unique biologic platform taps into virus-specific memory T cells to precisely target and eliminate harmful B cells, potentially offering patients a safer and more durable alternative. The collaboration marks a major step forward in both companies’ shared mission to bring smarter, more effective treatments to those facing chronic immune conditions.

With a $12 million upfront investment and the potential for over $345 million in milestone-based payments, Boehringer is placing a strong bet on Cue’s Immuno-STAT™ platform. “This partnership is about shifting the paradigm,” said Cue Biopharma CEO Daniel Passeri. “We’re aiming to harness the precision of the immune system to do what broad-spectrum treatments can’t.” Both companies also plan to explore broader applications across other B-cell driven autoimmune diseases, potentially redefining the treatment roadmap for millions worldwide.